(The Hill) – A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli ...

Of course, Lilly's most important new products are diabetes treatment Mounjaro and weight management medicine Zepbound, which share the active ingredient tirzepatide. In 2024, Eli Lilly's revenue ...

Throughout last year’s entertainment awards season, Lilly took aim at the popular off-label use of GLP-1 drugs like its Mounjaro and Zepbound for cosmetic weight loss. A commercial released ...

The marketing push underscores Lilly’s efforts to further define itself as a reliable developer and distributor of its approved weight loss drugs — Mounjaro and Zepbound — by contrasting them to ...

Eli Lilly is investing an additional $27 billion to boost domestic drug production as President Donald Trump reaffirms his commitment to imposing tariffs to restore manufacturing in the U.S. The ...

including the popular weight-loss drug Mounjaro. Eli Lilly said the investment will create 3,000 high-skilled positions and approximately 10,000 construction jobs. Eli Lilly has unveiled plans to ...

Lilly’s tirzepatide drugs, Zepbound for obesity and Mounjaro for diabetes, both of which are administered by injection, accounted for $5.4 billion in revenue in the fourth quarter alone.

The new investments aren't solely dedicated to Eli Lilly's current and future obesity and diabetes treatments. The company is charting its future beyond Zepbound and Mounjaro, with hopes to ...